St Jude Sets Sights On Year-End US Approval For NanoStim

Results of the LEADLESS II trial, presented at the European Society of Cardiology Congress in London, will support a US FDA premarket approval application for St Jude’s Nanostim leadless pacemaker by the end of 2015, the company says.

More from Archive

More from Medtech Insight